Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCCIH Development of Pregnenolone as a Treatment for Depression R61 Phase
NCT03645096Phase 1Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pregnenolone in major depressive disorder (MDD) (6 arms), sponsored by UT Southwestern Medical Center. Primary endpoints: Amygdala-Posterior Cingulate Cortex Functional Connectivity at 7 days, Dorsolateral Prefrontal Cortex-Insula Functional Connectivity at 7 days and 1 more. Started Sep 2019; status: completed.
02
Drugs
pregnenolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03645096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645096.